Javascript must be enabled to continue!
Effects of Chinese herbal medicine on Patients with AECOPD Risk Window: study protocol for a Randomized Controlled Trial
View through CrossRef
Abstract
Background
Chronic Obstructive Pulmonary Disease (COPD) is a major chronic disease with high incidence, mortality, and prevalence. Acute exacerbations mostly occur in a centralized period after an acute exacerbation, during which are extremely easy to occur again. We call this “high-risk period” as the “AECOPD risk window” (AECOPD-RW). At present, Western medicine lacks specific guidance on the medication of AECOPD-RW. Chinese herbal medicine has good efficacy and advantages in the treatment of COPD. Based on the clear distribution of syndrome in the previous period, this study aims to evaluate the clinical efficacy and safety of Chinese herbal medicine on AECOPD-RW.
Methods
This proposed study is a multi-center, double-blind, randomized controlled trial (RCT) to compare the efficacy of two therapies for patients with AECOPD-RW. 336 subjects will be randomly assigned in a 1:1 ratio to experimental group or control group for 8 weeks treatment and 18 weeks follow-up. Based on health education and conventional treatment, the experimental group will receive Chinese herbal medicine granule according to Chinese medicine syndrome types, while the control group will receive Chinese herbal medicine placebo granule according to Chinese medicine syndrome types. The primary outcomes are acute exacerbation rate in the AECOPD-RW, COPD Assessment Test (CAT) in the AECOPD-RW, and secondary outcomes include time to the first acute exacerbation, degree of acute exacerbation in the AECOPD-RW, acute exacerbation rate in the follow-up period, degree of acute exacerbation in the follow-up period, lung function, mMRC, quality of life and index of security. Outcome measurements will be evaluated at week 0, 8 of the treatment period and at week 16, 26 of the follow-up period. The results will provide evidence for the clinical efficacy and safety of traditional Chinese medicine in the treatment of AECOPD RW, and provide a reliable scheme for the treatment of AECOPD-RW.
Discussion
This is the first multicenter, randomized, double-blind, placebo-controlled parallel trial designed to investigate the efficacy of Chinese herbal medicine in the treatment of AECOPD-RW. The result of this RCT may help effectively reduce the possibility of AECOPD recurrence, change the course of disease deterioration, and provide evidence-based evidence for Chinese herbal medicine prevention and treatment of AECOPD-RW.
Trial registration
This trial was registered in ClinicalTrials.gov, NCT04851093. Registered on 14 April 2021.
Title: Effects of Chinese herbal medicine on Patients with AECOPD Risk Window: study protocol for a Randomized Controlled Trial
Description:
Abstract
Background
Chronic Obstructive Pulmonary Disease (COPD) is a major chronic disease with high incidence, mortality, and prevalence.
Acute exacerbations mostly occur in a centralized period after an acute exacerbation, during which are extremely easy to occur again.
We call this “high-risk period” as the “AECOPD risk window” (AECOPD-RW).
At present, Western medicine lacks specific guidance on the medication of AECOPD-RW.
Chinese herbal medicine has good efficacy and advantages in the treatment of COPD.
Based on the clear distribution of syndrome in the previous period, this study aims to evaluate the clinical efficacy and safety of Chinese herbal medicine on AECOPD-RW.
Methods
This proposed study is a multi-center, double-blind, randomized controlled trial (RCT) to compare the efficacy of two therapies for patients with AECOPD-RW.
336 subjects will be randomly assigned in a 1:1 ratio to experimental group or control group for 8 weeks treatment and 18 weeks follow-up.
Based on health education and conventional treatment, the experimental group will receive Chinese herbal medicine granule according to Chinese medicine syndrome types, while the control group will receive Chinese herbal medicine placebo granule according to Chinese medicine syndrome types.
The primary outcomes are acute exacerbation rate in the AECOPD-RW, COPD Assessment Test (CAT) in the AECOPD-RW, and secondary outcomes include time to the first acute exacerbation, degree of acute exacerbation in the AECOPD-RW, acute exacerbation rate in the follow-up period, degree of acute exacerbation in the follow-up period, lung function, mMRC, quality of life and index of security.
Outcome measurements will be evaluated at week 0, 8 of the treatment period and at week 16, 26 of the follow-up period.
The results will provide evidence for the clinical efficacy and safety of traditional Chinese medicine in the treatment of AECOPD RW, and provide a reliable scheme for the treatment of AECOPD-RW.
Discussion
This is the first multicenter, randomized, double-blind, placebo-controlled parallel trial designed to investigate the efficacy of Chinese herbal medicine in the treatment of AECOPD-RW.
The result of this RCT may help effectively reduce the possibility of AECOPD recurrence, change the course of disease deterioration, and provide evidence-based evidence for Chinese herbal medicine prevention and treatment of AECOPD-RW.
Trial registration
This trial was registered in ClinicalTrials.
gov, NCT04851093.
Registered on 14 April 2021.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and "AECOPD Risk-Window": study protocol for a randomized placebo-controlled trial
Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and "AECOPD Risk-Window": study protocol for a randomized placebo-controlled trial
Abstract
Background
Frequent chronic obstructive pulmonary disease (COPD) exacerbation is a major cause of hospital admission and mortality. It h...
Study of correlation of red cell distribution width with acute exacerbation of chronic obstructive pulmonary disease
Study of correlation of red cell distribution width with acute exacerbation of chronic obstructive pulmonary disease
Acute exacerbation of COPD is one of the most common disease in patients with infections, having frequent hospitalization. The aim of this study is to find whether there is any rel...
PERBANDINGAN EFEKTIVITAS PASTA GIGI HERBAL DENGAN PASTA GIGI NON HERBAL TERHADAP PENURUNAN INDEKS PLAK GIGI
PERBANDINGAN EFEKTIVITAS PASTA GIGI HERBAL DENGAN PASTA GIGI NON HERBAL TERHADAP PENURUNAN INDEKS PLAK GIGI
Abstract: Plaque control is an attempt to remove and prevent the plaque accumulation on the tooth surface. Brushing teeth is an effective method in controlling plaque. Plaque contr...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Effects of herbal tea (Platostoma palustre) on the Hyperlipidemia in vivo
Effects of herbal tea (Platostoma palustre) on the Hyperlipidemia in vivo
Platostoma palustre jelly is a traditional food. Platostoma palustre has been used as folk medicine and is effective against heat-shock, hypertension and diabetes. Therefore, the a...
Jianpi Huatan Tongfu granule alleviates inflammation and improves intestinal flora in patients with acute exacerbation of chronic obstructive pulmonary disease
Jianpi Huatan Tongfu granule alleviates inflammation and improves intestinal flora in patients with acute exacerbation of chronic obstructive pulmonary disease
Objectives
To investigate the clinical efficacy and mechanism of Jianpi Huatan Tongfu granule in treating acute exacerbation of chronic obstructive pulmonary di...

